Evidence map›Paper›PMID 39858963›Full record

ArticleMicroorganisms2025

First Detection and Genomic Characterization of Linezolid-Resistant

Tanya V Strateva, Preslava Hristova, Temenuga J Stoeva, Hristina Hitkova, Slavil Peykov

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Microorganisms, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Linezolid in the Focus of Antimicrobial Resistance ofInternational journal of molecular sciences · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Tanya V StratevaDepartment of Medical Microbiology "Corr. Mem. Prof. Ivan Mitov, MD, DMSc", Faculty of Medicine, Medical University of Sofia, 2 Zdrave Str., 1431 Sofia, Bulgaria.ORCID 0000-0002-5197-1849
Preslava HristovaDepartment of Microbiology and Virology, Faculty of Pharmacy, Medical University of Pleven, 1 St. Kliment Ohridski Str., 5800 Pleven, Bulgaria.
Temenuga J StoevaDepartment of Microbiology and Virology, Faculty of Medicine, Medical University of Varna, 55 Marin Drinov Str., 9002 Varna, Bulgaria.
Hristina HitkovaDepartment of Microbiology and Virology, Faculty of Pharmacy, Medical University of Pleven, 1 St. Kliment Ohridski Str., 5800 Pleven, Bulgaria.
Slavil PeykovDepartment of Medical Microbiology "Corr. Mem. Prof. Ivan Mitov, MD, DMSc", Faculty of Medicine, Medical University of Sofia, 2 Zdrave Str., 1431 Sofia, Bulgaria.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Linezolid is an oxazolidinone antibiotic and is considered a last-resort treatment option for serious infections caused by problematic Gram-positive pathogens, including vancomycin-resistant enterococci. The present study aimed to explore the linezolid resistance mechanisms and genomic characteristics of two vancomycin-susceptible

Indexed as

Enterococcus faecalisG2576T mutationhospital-adapted ST6 lineagelinezolid resistanceoptrApAR0780 plasmidST1102whole-genome sequencing

Identifiers

PMID39858963
PMCPMC11767806

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.